PRODUCT MONOGRAPh

medrol*®
methylprednisolone
4mg & 16mg tablets
USP
Glucocorticoid

Pfizer Canada Inc.
17 300 Trans-Canada Highway
Kirkland, Quebec H9J 2M5

Submission Control No: 202507

* TM Pharmacia Enterprises S.A.
  Pfizer Canada Inc., licensee
© Pfizer Canada Inc., 2017
# Table of Contents

## PART I: HEALTH PROFESSIONAL INFORMATION
- SUMMARY PRODUCT INFORMATION ................................................................. 3
- INDICATIONS AND CLINICAL USE ................................................................. 3
- CONTRAINDICATIONS ...................................................................................... 5
- WARNINGS AND PRECAUTIONS ................................................................. 5
- ADVERSE REACTIONS .................................................................................... 12
- DRUG INTERACTION ...................................................................................... 14
- DOSAGE AND ADMINISTRATION .................................................................. 18
- OVERDOSAGE .............................................................................................. 19
- ACTION AND CLINICAL PHARMACOLOGY .................................................. 20
- STORAGE AND STABILITY ........................................................................ 21
- DOSAGE FORMS, COMPOSITION AND PACKAGING .................................... 21

## PART II: SCIENTIFIC INFORMATION
- PHARMACEUTICAL INFORMATION ............................................................... 22
- TOXICOLOGY ................................................................................................ 22

## PART III: CONSUMER INFORMATION .......................................................... 24
PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

<table>
<thead>
<tr>
<th>Route of Administration</th>
<th>Dosage Form / Strength</th>
<th>Clinically Relevant Nonmedicinal Ingredients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral</td>
<td>Tablet 4mg, 16mg</td>
<td>calcium stearate, cornstarch, lactose, mineral oil, sucrose, and sorbic acid. Gluten-free. For a complete listing see Dosage Forms, Composition and Packaging section.</td>
</tr>
</tbody>
</table>

INDICATIONS AND CLINICAL USE

1. Endocrine Disorders

Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia. Nonsuppurative thyroiditis. Hypercalcemia associated with cancer.

2. Rheumatic Disorders

As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute non specific tenosynovitis; acute gouty arthritis; post-traumatic osteoarthritis; synovitis of osteoarthritis; epicondylitis.

3. Collagen Diseases

During an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus; systemic dermatomyositis (polymyositis); acute rheumatic carditis; polymyalgia rheumatica; giant cell arteritis.
4. **Dermatologic Diseases**

Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative dermatitis; mycosis fungoides; severe psoriasis; severe seborrheic dermatitis.

5. **Allergic States**

Control of severe of incapacitating allergic conditions intractable to adequate trials of conventional treatment: seasonal or perennial allergic rhinitis; serum sickness; bronchial asthma; drug hypersensitivity reactions; contact dermatitis; atopic dermatitis.

6. **Ophthalmic Diseases**

Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: allergic corneal marginal ulcers; herpes zoster ophthalmicus; anterior segment inflammation; diffuse posterior uveitis and choroiditis; sympathetic ophthalmia; allergic conjunctivitis; keratitis; chorioretinitis; optic neuritis; iritis and iridocyclitis.

7. **Gastrointestinal Diseases**

To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis.

8. **Respiratory Diseases**

Symptomatic sarcoidosis; Loeffler’s syndrome not manageable by other means; berylliosis; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; aspiration pneumonitis.

9. **Hematologic Disorders**

Idiopathic thrombocytopenic purpura in adults; secondary thrombocytopenia in adults; acquired (autoimmune) hemolytic anemia; erythroblastopenia (RBC anemia); congenital (erythroid) hypoplastic anemia.

10. **Neoplastic Diseases**

For palliative management of: leukemias and lymphomas in adults; acute leukemia of childhood.

11. **Edematous States**

To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.
12. **Nervous System**

Acute exacerbations of multiple sclerosis; management of edema associated with brain tumour.

13. **Miscellaneous**

Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement.

14. **Organ Transplantation**

**CONTRAINDICATIONS**

MEDROL is contraindicated:

- in patients with known hypersensitivity to any components of the product (see DOSAGE FORMS, COMPOSITION AND PACKAGING);
- in patients with systemic fungal infections;
- in patients administered with live or live, attenuated vaccines while receiving immunosuppressive doses of corticosteroids;
- in herpes simplex of the eye, except when used for short-term or emergency therapy as in acute sensitivity reactions;
- in patients with vaccinia and varicella, except when used for short-term or emergency therapy as in acute sensitivity reactions.

**WARNINGS AND PRECAUTIONS**

**General**

Patients should be advised to inform subsequent physicians of the prior use of MEDROL.

**Carcinogenesis and Mutagenesis**

Kaposi’s sarcoma has been reported to occur in patients receiving corticosteroid therapy. Discontinuation of corticosteroids may result in clinical remission.

Animal studies found corticosteroids to have possible tumorigenic and mutagenic potential (see TOXICOLOGY, Carcinogenic potential and also TOXICOLOGY, Mutagenic potential).

**Cardiovascular**

Adverse effects of glucocorticoids on the cardiovascular system, such as dyslipidemia and hypertension, may predispose treated patients with existing cardiovascular risk factors to additional cardiovascular effects, if high doses and prolonged courses are used. Accordingly,
corticosteroids should be employed judiciously in such patients and attention should be paid to risk modification and additional cardiac monitoring if needed.

Literature reports suggest an apparent association between the use of corticosteroids and left ventricular free wall rupture after a recent myocardial infarction; therefore, therapy with corticosteroids should be used with great caution in these patients.

Thrombosis including venous thromboembolism has been reported to occur with corticosteroids. As a result corticosteroids should be used with caution in patients who have or may be predisposed to thromboembolic disorders.

As sodium retention with resultant edema and potassium loss may occur in patients receiving corticosteroids, these agents should be used with caution in patients with congestive heart failure (use only if strictly necessary), hypertension, or renal insufficiency (see also WARNINGS AND PRECAUTIONS, Endocrine and Metabolism).

**Endocrine and Metabolism**
Corticosteroids can produce reversible HPA axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment. Drug induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstated.

In addition, acute adrenal insufficiency leading to a fatal outcome may occur if glucocorticoids are withdrawn abruptly. A steroid “withdrawal syndrome,” seemingly unrelated to adrenocortical insufficiency, may also occur following abrupt discontinuance of glucocorticoids. This syndrome includes symptoms such as: anorexia, nausea, vomiting, lethargy, headache, fever, joint pain, desquamation, myalgia, weight loss, and/or hypotension. These effects are thought to be due to the sudden change in glucocorticoid concentration rather than to low corticosteroid levels.

Drug-induced adrenocortical insufficiency may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstated. Since mineralocorticoid secretion may be impaired, salt and/or mineralocorticoid should be administered concurrently.

Because glucocorticoids can produce or aggravate Cushing’s syndrome, glucocorticoids should be avoided in patients with Cushing’s disease.

Average and large doses of cortisone or hydrocortisone can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium. These effects are less likely to occur with the synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion. See also WARNINGS AND PRECAUTIONS, Cardiovascular.
There is an enhanced effect of corticosteroids on patients with hypothyroidism. Metabolic clearance of corticosteroids is decreased in hypothyroid patients and increased in hyperthyroid patients. Changes in thyroid status of the patient may necessitate adjustment in dosage.

Corticosteroids, including methylprednisolone, can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term corticosteroid therapy to diabetes mellitus.

Pheochromocytoma crisis, which can be fatal, has been reported after administration of systemic corticosteroids, including methylprednisolone. Corticosteroids should only be administered to patients with suspected or identified pheochromocytoma after an appropriate risk/benefit evaluation.

**Gastrointestinal**

Glucocorticoid therapy may mask the symptoms of peptic ulcer so that perforation or hemorrhage may occur without significant pain. Glucocorticoid therapy may mask peritonitis or other signs or symptoms associated with gastrointestinal disorders such as perforation, obstruction or pancreatitis. In combination with NSAIDs (such as Aspirin), the risk of developing gastrointestinal ulcers is increased.

Corticosteroids should be used with caution in: nonspecific ulcerative colitis if there is a probability of impending perforation, abscess or other pyogenic infection and in diverticulitis; fresh intestinal anastomoses and active or latent peptic ulcer when steroids are used as direct or adjunctive therapy, since they may increase the risk of a perforation. Signs of peritoneal irritation following gastrointestinal perforation in patients receiving corticosteroids may be minimal or absent.

**Hematologic**

Acetylsalicylic acid should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia. See also DRUG INTERACTIONS.

**Hepatic/Biliary/Pancreatic**

There is an enhanced effect of corticosteroids on patients with cirrhosis.

High doses of corticosteroids may produce acute pancreatitis.

Hepatobiliary disorders have been reported which may be reversible after discontinuation of therapy. Therefore appropriate monitoring is required.

**Immune**

Corticosteroids may suppress the immune system and increase susceptibility to infection, may mask some signs of infection, and new infections may appear during their use. There may be decreased resistance and inability to localize infection when corticosteroids are used. Infections with any pathogen including viral, bacterial, fungal, protozoan or helminthic organisms, in any location in the body, may be associated with the use of corticosteroids alone or in combination.
with other immunosuppressive agents that affect cellular immunity, humoral immunity or neutrophil function. These infections may be mild, but can be severe and at times fatal. With increasing doses of corticosteroids, the rate of occurrence of infectious complication increases.

**Fungal Infections**
Corticosteroids may exacerbate systemic fungal infections and therefore should not be used in the presence of such infections. There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure (see CONTRAINDICATIONS; DRUG INTERACTIONS).

**Special pathogens**
Latent disease may be activated or there may be an exacerbation of intercurrent infections due to pathogens, including those caused by *Amoeba, Candida, Cryptococcus, Mycobacterium, Nocardia, Pneumocystis, Taxoplasma*.

It is recommended that latent amebiasis or active amebiasis be ruled out before initiating corticosteroid therapy in any patient who has spent time in the tropics or in any patient with unexplained diarrhea.

Similarly, corticosteroids should be used with great care in patients with known or suspected *Strongyloides* (threadworm) infestation. In such patients, corticosteroid-induced immunosuppression may lead to *Strongyloides* hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.

Corticosteroids should not be used in cerebral malaria. There is currently no evidence of benefit from steroids in this condition.

**Tuberculosis**
The use of corticosteroids in active tuberculosis should be restricted to those cases of fulminating or disseminated tuberculosis in which the corticosteroid is used for the management of the disease in conjunction with an appropriate antituberculosis regimen. If corticosteroids are indicated in patients with latent tuberculosis reactivity, close observation is necessary as reactivation of the disease may occur. During prolonged corticosteroid therapy, these patients should receive chemoprophylaxis.

**Vaccinations**
Administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids (see CONTRAINDICATIONS). Killed or inactivated vaccines may be administered; however, the response to such vaccines may be diminished. Indicated immunization procedures may be undertaken in patients receiving non immunosuppressive doses of corticosteroids.

While on corticosteroid therapy patients should not be vaccinated against smallpox. Other immunization procedures should not be undertaken in patients who are on corticosteroids,
especially in high doses, because of possible hazards of neurological complications and lack of antibody response.

**Viral Infections**

Chicken pox and measles, for example, can have a more serious or even fatal course in non-immune children or adults on corticosteroids. In pediatric and adult patients who have not had these diseases, particular care should be taken to avoid exposure. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known. If exposed to chicken pox, prophylaxis with varicella zoster immune globulin (VZIG) may be indicated. If exposed to measles, prophylaxis with immunoglobulin (IG) may be indicated. (See the respective package inserts for complete VZIG and IG prescribing information.) If chicken pox develops, treatment with antiviral agents should be considered.

Recent studies do not support MEDROL use during septic shock, and suggest that increased mortality may occur in some subgroups at higher risk (e.g., elevated serum creatinine greater than 2.0 mg/dL or secondary infections).

**Musculoskeletal**

An acute myopathy has been reported with the use of high doses of corticosteroids, most often occurring in patients with disorders of neuromuscular transmission (e.g., myasthenia gravis), or in patients receiving concomitant therapy with anticholinergics, such as neuromuscular blocking drugs (e.g., pancuronium). This acute myopathy is generalized, may involve ocular and respiratory muscles, and may result in quadriplegia. Elevations of creatine kinase may occur. Clinical improvement or recovery after stopping corticosteroids may require weeks to years.

Corticosteroids decrease bone formation and increase bone resorption both through their effect on calcium regulation (e.g., decreasing absorption and increasing excretion) and inhibition of osteoblast function. This, together with a decrease in protein matrix of the bone secondary to an increase in protein catabolism, and reduced sex hormone production, may lead to inhibition of bone growth in pediatric patients and the development of osteoporosis at any age. Special consideration should be given to increased risk of osteoporosis (e.g., postmenopausal women) before initiating corticosteroid therapy. Osteoporosis is a common but infrequently recognized adverse effect associated with a long-term use of glucocorticoids.

**Neurologic**

Corticosteroids should be used with caution in patients with seizure disorders.

Convulsions have been reported with concurrent use of methylprednisolone and cyclosporine. Since concurrent administration of these agents results in a mutual inhibition of metabolism, it is possible that convulsions and other adverse events associated with the individual use of either drug may be more apt to occur.

Systemic corticosteroids are not indicated for, and therefore should not be used to treat traumatic brain injury, a multicenter study revealed an increased mortality at 2 weeks and 6 months after
injury in patients administered methylprednisolone sodium succinate compared to placebo. A causal association with methylprednisolone sodium succinate treatment has not been established.

There have been reports of epidural lipomatosis in patients taking corticosteroids (including cases in children).

Corticosteroids should be used with caution in patients with myasthenia gravis.

**Ophthalmologic**
Use of corticosteroids may produce posterior sub-capsular cataracts and nuclear cataracts (particularly in children), exophthalmos, or increased intraocular pressure, which may result in glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to fungi or viruses. As intraocular pressure may become elevated in some individuals, if steroid therapy is continued for more than 6 weeks, intraocular pressure should be monitored. The use of systemic corticosteroids is not recommended in the treatment of optic neuritis and may lead to an increase in the risk of new episodes. Corticosteroids should be used cautiously in patients with ocular herpes simplex because of possible corneal perforation. Corticosteroids should not be used in active ocular herpes simplex.

Corticosteroid therapy has been associated with central serous chorioretinopathy, which may lead to retinal detachment.

**Psychiatric**
Psychic derangements may appear when corticosteroids are used ranging from euphoria, insomnia, mood swings, personality changes, and severe depression to frank psychotic manifestations. Also existing emotional instability or psychotic tendencies may be aggravated by corticosteroids, and therefore these patients should be treated with caution.

Potentially severe psychiatric adverse reactions may occur with systemic steroids (see ADVERSE REACTIONS). Symptoms typically emerge within a few days or weeks of starting treatment. Most reactions recover after either dose reduction or withdrawal, although specific treatment may be necessary. Psychological effects have been reported upon withdrawal of corticosteroids; the frequency is unknown. Patients/caregivers should be encouraged to seek medical attention if psychological symptoms develop in the patient, especially if depressed mood or suicidal ideation is suspected. Patients/caregivers should be alert to possible psychiatric disturbances that may occur either during or immediately after dose tapering/withdrawal of systemic steroids.

**Sensitivity/Resistance**
Allergic reactions (e.g., angioedema) may occur. Because rare instances of skin reactions and anaphylactic/anaphylactoid reactions have occurred in patients receiving corticosteroid therapy, appropriate precautionary measures should be taken prior to administration, especially when the patient has a history of allergy to any drug.
**Sexual Function/Reproduction**
Steroids may increase or decrease motility and number of spermatozoa in some patients.

**Special Populations**

**Pregnant Women:** Corticosteroids readily cross the placenta. Corticosteroids have been shown to be teratogenic in many species when given in doses equivalent to human dose. Animal studies in which corticosteroids have been given to pregnant mice, rats, rabbits have yielded an increase incidence of cleft palate in the offspring (see TOXICOLOGY, Reproductive toxicity).

One retrospective study found an increased incidence of low birth weights in infants born of mothers receiving corticosteroids. Cataracts have been observed in infants born to mothers undergoing long-term treatment with corticosteroids during pregnancy.

Since adequate human reproductive studies have not been done with methylprednisolone, this drug should be used during pregnancy at the lowest possible dose, only if clearly needed, where the potential benefit to the mother justifies the potential risk to the embryo or fetus.

Infants born to mothers who have received substantial doses of corticosteroids during pregnancy must be carefully observed and evaluated for signs of adrenal insufficiency. There are no known effects of corticosteroids on labour and delivery.

**Nursing Women:** Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. Because of the potential for serious adverse reactions in nursing infants from corticosteroids, a careful benefit-risk assessment should be conducted and a decision should be made whether to discontinue nursing, or discontinue the drug, taking into account the importance of the drug to the mother.

**Pediatrics:** Growth may be suppressed in children receiving long-term daily, divided dose glucocorticoid therapy and use of such regimen should be restricted to the most urgent indication. Alternate day glucocorticoid therapy may minimize this side effect (see DOSAGE AND ADMINISTRATION, Alternate Day Therapy). Pediatric patients may experience a decrease in their growth velocity at low systemic doses and in the absence of laboratory evidence of hypothalamic-pituitary-adrenal (HPA) axis suppression. Growth velocity may therefore be a more sensitive indicator of systemic corticosteroid exposure in pediatric patients than some commonly used tests of HPA axis function. In order to minimize the potential growth effects of corticosteroids, pediatric patients should be titrated to the lowest effective dose.

Growth and development of infants and children on prolonged corticosteroid therapy should be carefully observed. Like adults, pediatric patients should be carefully observed with frequent measurements of blood pressure, weight, height, intraocular pressure, and clinical evaluation for the presence of infection, psychosocial disturbances, thromboembolism, peptic ulcers, cataracts, and osteoporosis.
Infants and children on prolonged corticosteroid therapy are at special risk from raised intracranial pressure.

High doses of corticosteroids may produce pancreatitis in children.

**Monitoring and Laboratory Tests**

Corticosteroids may suppress reactions to skin tests.

Since methylprednisolone suppresses endogenous adrenocortical activity, it is highly important that the patient receiving MEDROL be under careful observation, not only during the course of treatment but for some time after treatment is terminated. Monitoring for signs and symptoms of drug-induced secondary adrenocortical insufficiency may be necessary for up to one year following cessation of long-term or high-dose corticosteroid therapy.

**ADVERSE REACTIONS**

Note: The following are typical for all systemic corticosteroids. Their inclusion in this list does not necessarily indicate that the specific event has been observed with this particular formulation.

**Allergic reactions**: Allergic or hypersensitivity reactions, anaphylactoid reaction, anaphylaxis, angioedema.

**Blood and lymphatic system disorders**: Leukocytosis.

**Cardiovascular**: Bradycardia, cardiac arrest, cardiac arrhythmias, cardiac enlargement, circulatory collapse, congestive heart failure, fat embolism, hypertension, hypotension, hypertrophic cardiomyopathy in premature infants, myocardial rupture following recent myocardial infarction, pulmonary edema, syncope, tachycardia, thromboembolism, thrombophlebitis, thrombosis, vasculitis.

**Dermatologic**: Acne, allergic dermatitis, cutaneous and subcutaneous atrophy, dry scaly skin, ecchymoses and petechiae, edema, erythema, hyperpigmentation, hypopigmentation, impaired wound healing, increased sweating, rash, pruritus, sterile abscess, striae, suppressed reactions to skin tests, thin fragile skin, thinning scalp hair, and urticaria. Kaposi’s sarcoma has been reported to occur in patients receiving corticosteroid therapy.

**Endocrine**: Decreased carbohydrate and glucose tolerance, development of cushingoid state, moon face, weight gain, abnormal fat deposits, glycosuria, hirsutism, hypertrichosis, increased requirements for insulin or oral hypoglycemic agents in diabetes, manifestations of latent diabetes mellitus, menstrual irregularities, secondary adrenocortical and pituitary unresponsiveness (particularly in times of stress, as in trauma, surgery, or illness), suppression of growth in pediatric patients, metabolic acidosis.
A steroid “withdrawal syndrome,” seemingly unrelated to adrenocortical insufficiency, may also occur following abrupt discontinuance of glucocorticoids. This syndrome includes symptoms such as: anorexia, nausea, vomiting, lethargy, headache, fever, joint pain, desquamation, myalgia, weight loss, and/or hypotension. These effects are thought to be due to the sudden change in glucocorticoid concentration rather than to low corticosteroid levels.

**Fluid and electrolyte disturbances:** Sodium retention, fluid retention, congestive heart failure in susceptible patients, potassium loss, urine calcium increased hypokalemic alkalosis.

**Gastrointestinal:** Abdominal distention, abdominal pain, diarrhea, dyspepsia, bowel/bladder dysfunction (after intrathecal administration), increased appetite, nausea, pancreatitis, peptic ulcer with possible subsequent perforation and hemorrhage, perforation of the small and large intestine (particularly in patients with inflammatory bowel disease), gastric hemorrhage, esophagitis, ulcerative esophagitis, peritonitis (peritonitis may be the primary presenting sign or symptom of a gastrointestinal disorder such as perforation, obstruction or pancreatitis).

**Hepatic:** Increases in alanine transaminase (ALT, SGPT), aspartate transaminase (AST, SGOT) and alkaline phosphatase have been observed following corticosteroid treatment. These changes are usually small, not associated with any clinical syndrome and are reversible upon discontinuation. Hepatomegaly has also been observed.

**Immune system:** Masking of infections, decreased resistance to infection, latent infections becoming active, opportunistic infections, hypersensitivity reactions including anaphylaxis, may suppress reactions to skin tests.

**Investigations:** Blood urea increased, suppression of reactions to skin tests.

**Metabolic:** Negative nitrogen balance due to protein catabolism, dyslipidemia.

**Musculoskeletal:** Arthralgia, aseptic necrosis of femoral and humeral heads, calcinosis (following intra-articular or intralesional use), Charcot-like arthropathy, myalgia, loss of muscle mass, muscle weakness, malaise, osteoporosis, pathologic fracture of long bones, steroid myopathy, tendon rupture, particularly of the Achilles tendon, vertebral compression fractures.

**Neurologic/Psychiatric:** Convulsions, headache, dizziness, vertigo, amnesia, cognitive disorder, increased intracranial pressure with papilledema (pseudotumor cerebri) usually following discontinuation of treatment, neuritis, neuropathy, paresthesia, epidural lipomatosis, insomnia, mood swings, depression, emotional instability, euphoria, abnormal behavior, personality changes, psychological dependence, psychic disorders, affect lability, suicidal ideation, anxiety, confusional state, psychotic behavior, mania, delusion, hallucination, schizophrenia (aggravation of).

**Ophthalmic:** Cataracts, increased intraocular pressure, glaucoma, exophthalmos, central serous chorioretinopathy.
**Reproductive System:** Increased or decreased motility and number of spermatozoa, menstruation irregular.

**Other:** Fatigue, hiccups, pulmonary embolism, oedema peripheral

**DRUG INTERACTIONS**

**Overview**
Methylprednisolone is a cytochrome P450 enzyme (CYP) substrate and is mainly metabolized by the CYP3A4 enzyme. CYP3A4 is the dominant enzyme of the most abundant CYP subfamily in the liver of adult humans. It catalyzes 6β-hydroxylation of steroids, the essential Phase I metabolic step for both endogenous and synthetic corticosteroids.

CYP3A4 SUBSTRATES - Many compounds are also substrates of CYP3A4, some of which (as well as other drugs) have been shown to alter glucocorticoid metabolism by induction (up regulation) or inhibition of the CYP3A4 enzyme. In the presence of another CYP3A4 substrate, the hepatic clearance of methylprednisolone may be affected, with corresponding dosage adjustments required. It is possible that adverse events associated with the use of either drug alone may be more likely to occur with coadministration.

CYP3A4 INHIBITORS - Drugs that inhibit CYP3A4 activity, such as ketoconazole, erythromycin, clarithromycin, diltiazem, and cyclosporine (see Table 1 below), generally decrease hepatic clearance and increase the plasma concentration of CYP3A4 substrate medications, such as methylprednisolone. In the presence of a CYP3A4 inhibitor, a lower dose of methylprednisolone may be required to avoid toxicity.

CYP3A4 INDUCERS - Drugs that induce CYP3A4 activity, such as Phenobarbital, rifampin, carbamazepine, and phenytoin (see Table 1 below), generally increase hepatic clearance, resulting in decreased plasma concentration of medications that are substrates for CYP3A4. Coadministration may require an increase in methylprednisolone dosage to achieve the desired result.

Withdrawal of these inhibitors or inducers reverses these clinical changes and may require careful dosage re-adjustment.

**Drug-Drug Interactions**

NON-CYP3A4-MEDIATED EFFECTS – Other interactions and effects that occur with methylprednisolone are described in Table 1 below.
Table 1 provides a list and descriptions of the most common and/or clinically important drug interactions or effects with methylprednisolone.

Table 1. Important drug interactions/effects with methylprednisolone

<table>
<thead>
<tr>
<th>Drug Class or Type - DRUG</th>
<th>Interaction/Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antibacterial</strong> - ISONIAZID</td>
<td>CYP3A4 INHIBITOR. In addition, there is a potential effect of methylprednisolone to increase the acetylation rate and clearance of isoniazid.</td>
</tr>
<tr>
<td><strong>Antibiotic</strong> - RIFAMPIN</td>
<td>CYP3A4 INDUCER. Drugs which induce cytochrome P450 3A4 enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.</td>
</tr>
<tr>
<td><strong>Anticoagulants (oral)</strong></td>
<td>The effect of methylprednisolone on oral anticoagulants is variable. There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids. Coadministration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports. Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effects.</td>
</tr>
<tr>
<td><strong>Anticonvulsants</strong> - CARBAMAZEPINE</td>
<td>CYP3A4 INDUCER (and SUBSTRATE). Drugs which induce cytochrome P450 3A4 enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.</td>
</tr>
<tr>
<td><strong>Anticonvulsants</strong> - PHENOBARBITAL - PHENYTOIN</td>
<td>CYP3A4 INDUCERS. Drugs which induce cytochrome P450 3A4 enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.</td>
</tr>
<tr>
<td><strong>Anticholinergics</strong> - NEUROMUSCULAR BLOCKERS</td>
<td>Corticosteroids may influence the effect of anticholinergics. 1) An acute myopathy has been reported with the concomitant use of high doses of corticosteroids and anticholinergics, such as neuromuscular blocking drugs. (see WARNINGS AND PRECAUTIONS, Musculoskeletal and connective tissue disorders) 2) Antagonism of the neuromuscular blocking effects of pancuronium and vecuronium has been reported in patients taking corticosteroids. This interaction may be expected with all competitive neuromuscular blockers.</td>
</tr>
<tr>
<td><strong>Anticholinesterases</strong></td>
<td>Steroids may reduce the effects of anticholinesterases in myasthenia gravis. Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy.</td>
</tr>
<tr>
<td><strong>Antidiabetics</strong></td>
<td>Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required.</td>
</tr>
<tr>
<td><strong>Antiemetic</strong> - APREPITANT - FOSAPREPITANT</td>
<td>CYP3A4 INHIBITORS (and SUBSTRATES). Drugs which inhibit cytochrome P450 3A4 have the potential to result in increased plasma concentrations of corticosteroids. Therefore the dose of methylprednisolone should be titrated to avoid steroid toxicity.</td>
</tr>
<tr>
<td>Drug Class or Type - DRUG</td>
<td>Interaction/Effect</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Antitubercular Drugs</td>
<td></td>
</tr>
<tr>
<td>• ISONIAZID</td>
<td>CYP3A4 INDUCER</td>
</tr>
<tr>
<td></td>
<td>Serum concentrations of isoniazid may be decreased. Drugs which induce cytochrome P450 3A4 enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.</td>
</tr>
<tr>
<td>Aromatase inhibitors</td>
<td></td>
</tr>
<tr>
<td>- AMINOGlutETHIMIDE</td>
<td>Aminoglutethimide-induced adrenal suppression may exacerbate endocrine changes caused by prolonged glucocorticoid treatment. Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression.</td>
</tr>
<tr>
<td>Calcium Channel Blocker</td>
<td>CYP3A4 INHIBITOR (and SUBSTRATE)</td>
</tr>
<tr>
<td>- DILTIAZEM</td>
<td></td>
</tr>
<tr>
<td>Contraceptives (oral)</td>
<td>CYP3A4 INHIBITOR (and SUBSTRATE)</td>
</tr>
<tr>
<td>- ETHINYLESTRADIOL/</td>
<td>Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.</td>
</tr>
<tr>
<td>- Norethindrone</td>
<td></td>
</tr>
<tr>
<td>Digitalis glycosides</td>
<td>Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia.</td>
</tr>
<tr>
<td>Ímmunosuppressant</td>
<td>CYP3A4 INHIBITOR (and SUBSTRATE)</td>
</tr>
<tr>
<td>- CYCLOSPORINE</td>
<td>1) Mutual inhibition of metabolism occurs with concurrent use of cyclosporine and methylprednisolone, which may increase the plasma concentrations of either or both drugs. Therefore, it is possible that adverse events associated with the use of either drug alone may be more likely to occur upon coadministration.</td>
</tr>
<tr>
<td></td>
<td>2) Convulsions have been reported with concurrent use of methylprednisolone and cyclosporine.</td>
</tr>
<tr>
<td></td>
<td>3) Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently.</td>
</tr>
<tr>
<td>Ímmunosuppressant</td>
<td>CYP3A4 SUBSTRATES</td>
</tr>
<tr>
<td>- CYCLOPHOSPHAMIDE</td>
<td></td>
</tr>
<tr>
<td>- TACROlimUS</td>
<td></td>
</tr>
<tr>
<td>Macrolide Antibacterial</td>
<td>CYP3A4 INHIBITORS (and SUBSTRATES)</td>
</tr>
<tr>
<td>- CLARITHROMYCIN</td>
<td>Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance. Drugs which inhibit cytochrome P450 3A4 have the potential to result in increased plasma concentrations of corticosteroids. Therefore the dose of methylprednisolone should be titrated to avoid steroid toxicity.</td>
</tr>
<tr>
<td>- ERYTHROMYCIN</td>
<td></td>
</tr>
</tbody>
</table>
**Drug Class or Type - DRUG** | **Interaction/Effect**
---|---
Ketoconazole | Ketoconazole has been reported to significantly decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects.

NSAIDs (nonsteroidal anti-inflammatory drugs)  
- high-dose ASA (acetylsalicylic acid) | 1) There may be increased incidence of gastrointestinal bleeding and ulceration when corticosteroids are given with NSAIDs.  
2) Methylprednisolone may increase the clearance of high-dose ASA. This decrease in salicylate serum levels could lead to an increased risk of salicylate toxicity when methylprednisolone is withdrawn. ASA should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprolthrombocinemia.

Potassium-depleting agents | When corticosteroids are administered concomitantly with potassium-depleting agents (i.e., diuretics), patients should be observed closely for development of hypokalemia. There is also an increased risk of hypokalemia with concurrent use of corticosteroids with amphotericin B, xanthenes, or beta2 agonists.  
There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure.

Antivirals  
- HIV-PROTEASE INHIBITORS | CYP3A4 INHIBITORS (and SUBSTRATES)  
1) Protease inhibitors, such as indinavir and ritonavir, may increase plasma concentrations of corticosteroids.  
2) Corticosteroids may induce the metabolism of HIV-protease inhibitors resulting in reduced plasma concentrations.

Cholestyramine | Cholestyramine may increase the clearance of oral corticosteroids.

Vaccines | Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or attenuated vaccines due to inhibition of antibody response. Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines. Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see WARNINGS AND PRECAUTIONS: Infections, Vaccinations).

---

**Drug-Food Interactions**

Grapefruit juice is a CYP3A4 inhibitor. See DRUG INTERACTIONS: CYP3A4 INHIBITORS above.

**Drug-Laboratory Interactions**

Corticosteroids may suppress reactions to skin tests.

**Drug-Lifestyle Interactions**

Dizziness, vertigo, visual disturbances and fatigue are possible side effects associated with corticosteroid use. If affected, patients should not drive or operate machinery.
DOSAGE AND ADMINISTRATION

Dosing Considerations
Because complications of treatment with glucocorticoids are dependent on the size of the dose and the duration of treatment, a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used.

Patients should be advised to inform subsequent physicians of the prior use of MEDROL.

The existence of diabetes, osteoporosis, renal insufficiency, chronic psychosis, cardiovascular disease, myasthenia gravis or predisposition to thrombophlebitis requires that MEDROL be administered with caution.

Geriatrics: Dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Recommended Dose and Dosage Adjustment
The initial dosage of MEDROL tablets may vary from 4 to 48 mg as methylprednisolone per day depending on the specific disease entity being treated. The lowest possible dose of corticosteroid should be used to control the condition under treatment.

If after a reasonable period of time there is lack of satisfactory clinical response, MEDROL tablets should be discontinued and the patient transferred to other appropriate therapy. If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly.

After a favourable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached. It should be kept in mind that constant monitoring is needed in regard to drug dosage.

Dosage adjustments may be required based on the following:
- during remission
- exacerbation of the disease process
- the patient’s individual response to therapy
- upon exposure of the patient to emotional or physical stress such as serious infection, surgery or injury. MEDROL dosage may need to be increased during and after the stressful situation.

It should be emphasized that dosage requirements are variable and must be individualized on the basis of the disease under treatment and the response of the patient.
**Alternate Day Therapy**: Alternate day therapy is a corticosteroid dosing regimen in which twice the usual daily dose of corticosteroid is administered every other morning.

The purpose of this mode of therapy is to provide a patient requiring long-term, pharmacologic dose treatment with the beneficial effects of corticoids while minimizing certain undesirable effects, including pituitary-adrenal suppression, the cushingoid state, corticoid withdrawal symptoms, and growth suppression in children.

**Missed Dose**

If a patient misses a dose, advise them to take the dose as soon as possible. If it is almost time for the patient’s next dose, advise the patient to skip the missed dose and go back to their normal schedule. Patients should not take 2 doses at the same time.

**OVERDOSAGE**

Treatment of acute overdosage is by supportive and symptomatic therapy. For chronic overdosage in the face of severe disease requiring continuous steroid therapy, the dosage of corticosteroid may be reduced only temporarily. Methylprednisolone is dialyzable.

For management of a suspected drug overdose, contact your regional Poison Control Centre.
ACTION AND CLINICAL PHARMACOLOGY

Pharmacodynamics
Methylprednisolone is a potent anti-inflammatory steroid. It has greater anti-inflammatory potency than prednisolone and less tendency than prednisolone to induce sodium and water retention. The relative potency of methylprednisolone to hydrocortisone is at least four to one.

Pharmacokinetics
Methylprednisolone pharmacokinetics is linear, independent of route of administration.

Absorption: Methylprednisolone is rapidly absorbed and the maximum plasma methylprednisolone concentration is achieved around 1.5 to 2.3 hours across doses following oral administration in normal healthy adults. The absolute bioavailability of methylprednisolone in normal healthy subjects is generally high (82% to 89%) following oral administration.

Distribution: Methylprednisolone is widely distributed into the tissues, crosses the blood-brain barrier, and is secreted in breast milk. Its apparent volume of distribution is approximately 1.4L/kg. The plasma protein binding of methylprednisolone in humans is approximately 77%.

Metabolism: In humans, methylprednisolone is metabolized in the liver to inactive metabolites; the major ones are 20α-hydroxymethylprednisolone and 20β-hydroxymethylprednisolone. Metabolism in the liver occurs primarily via the CYP3A4 enzyme (see DRUG INTERACTIONS).

Methylprednisolone, like many CYP3A4 substrates, may also be a substrate for the ATP-binding cassette (ABC) transport protein p-glycoprotein, influencing tissue distribution and interactions with other medicines.

Excretion: The mean elimination half-life for total methylprednisolone is in the range of 1.8 to 5.2 hours. Total clearance is approximately 5 to 6 mL/min/kg.
STORAGE AND STABILITY
Store at controlled room temperature (15°C to 30°C).

Keep in a safe place out of the reach and sight of children.

DOSAGE FORMS, COMPOSITION AND PACKAGING
Each elliptical, cross-scored tablet contains: methylprednisolone 4 mg (white, engraved “Medrol 4”) or 16 mg (white, engraved “Medrol 16”).

Nonmedicinal ingredients: calcium stearate, cornstarch, lactose, mineral oil and sucrose. In addition, the 4 mg tablet contains sorbic acid. Gluten-free.

Available in bottles of 100 tablets.
PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance

Proper name: methylprednisolone
Chemical name: pregna-1,4-diene-3,20-dione, 11, 17, 21-trihydroxy-6-methyl-, (6α, 11β)
Molecular formula and molecular mass: \( \text{C}_{22}\text{H}_{30}\text{O}_{5} \) and 374.5

Structural formula:

\[ \text{Structure Image} \]

Physicochemical properties: white crystal powder

TOXICOLOGY

Conventional studies of safety, pharmacology and repeated- dose toxicity using intravenous, intraperitoneal, subcutaneous, intramuscular, and oral routes of administration, were done in mice, rats, rabbits and dogs using methylprednisolone sodium succinate. The toxicities seen in the repeated-dose studies are those expected to occur with continued exposure to exogenous adrenocortical steroids.

Carcinogenic potential

Methylprednisolone has not been evaluated in rodent carcinogenicity studies.

Variable results have been obtained with other glucocorticoids tested for carcinogenicity in mice and rats. However, published data indicate that several related glucocorticoids including budesonide, prednisolone, and triamcinolone acetonide can increase the incidence of hepatocellular adenomas and carcinomas after oral administration in drinking water to male rats.
These tumorigenic effects occurred at doses which were less than the typical clinical doses on a mg/m² basis.

**Mutagenic potential**

Methylprednisolone has not been evaluated for genotoxicity.

However, methylprednisolone sulfonate, which is structurally similar to methylprednisolone sodium succinate, was not mutagenic with or without metabolic activation in *Salmonella typhimurium*, or in a mammalian cell gene mutation assay using Chinese hamster ovary cells. Methylprednisolone suleptanate did not induce unscheduled DNA synthesis in primary rat hepatocytes. Moreover, a review of published data indicates that prednisolone farnesylate (PNF), which is structurally similar to methylprednisolone, was not mutagenic with or without metabolic activation in *Salmonella typhimurium* and *Escherichia coli* strains. In a Chinese hamster fibroblast cell line, PNF produced a slight increase in the incidence of structural chromosomal aberrations with metabolic activation at the highest concentration tested.

**Reproductive toxicity**

Corticosteroids have been shown to reduce fertility when administered to rats. Male rats were administered corticosterone at doses of 0, 10, and 25 mg/kg/day by subcutaneous injection once daily for 6 weeks and mated with untreated females. The high dose was reduced to 20 mg/kg/day after Day 15. Decreased copulatory plugs were observed, which may have been secondary to decreased accessory organ weight. The numbers of implantations and live fetuses were reduced in untreated females mated with males treated at the administered doses of 10 and 25 mg/kg/day.

Corticosteroids have been shown to be teratogenic in many species when given in doses equivalent to the human dose. In animal reproduction studies, glucocorticoids such as methylprednisolone have been shown to increase the incidence of malformations (cleft palate, skeletal malformations), embryo-fetal lethality (e.g., increase in resorptions), and intra-uterine growth retardation.
PART III: CONSUMER INFORMATION

**MEDROL***
(methylprednisolone tablets USP)
4 mg and 16 mg Tablets

This leaflet is part III of a three-part "Product Monograph" published when MEDROL was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about MEDROL. Contact your doctor or pharmacist if you have any questions about the drug.

ABOUT THIS MEDICATION

What the medication is used for:
MEDROL is used in the treatment of various conditions such as allergy or inflammation; it can also be used to replace corticosteroid hormone when the body does not produce enough due to problems with the adrenal glands (e.g. adrenal insufficiency)

What it does:
MEDROL contains a corticosteroid hormone. It decreases the body’s immune response to certain diseases and reduces symptoms such as swelling and redness.

When it should not be used:
Do not take MEDROL if you have:
- allergies to methylprednisolone or any other steroid medicine or any of the ingredients in MEDROL tablets; or
- any fungal infection. 
- viral diseases including vaccinia (cowpox), varicella (chicken pox), and herpes simplex of the eye.

Patients taking MEDROL should not receive live vaccines.

What the medicinal ingredient is:
Methylprednisolone

What the nonmedicinal ingredients are:
Calcium stearate, cornstarch, lactose, mineral oil and sucrose. In addition, the 4 mg tablet contains sorbic acid.

What dosage forms it comes in:
Each elliptical, cross-scored tablet contains: methylprednisolone 4 mg (white, engraved “Medrol 4”) or 16 mg (white, engraved “Medrol 16”).

WARNINGS AND PRECAUTIONS

Before taking MEDROL, talk to your doctor if you have:
- an infection (such as herpes simplex, chicken pox, tuberculosis, threadworm);
- recently had myocardial infarction (heart attack)
- thromboembolic disorders (bleeding or blood clotting problems)
- brittle bone (osteoporosis);
- high blood pressure
- water retention (oedema);
- heart problems such as heart failure;
- kidney disease;
- diabetes;
- seizures (fits) or other neurological problems;
- thyroid problems;
- muscle pain or weakness (such as myasthenia gravis);
- skin cancer (Kaposi’s sarcoma), or a tumor of the adrenal glands (Pheochromocytoma);
- certain eye disease such as glaucoma, cataracts; herpes infection or any problems with the retina;
- liver disease such as cirrhosis;
- certain mental or mood conditions (such as depression)
- stomach or gut problems (ulcer, ulcerative colitis);
- low potassium or calcium;
- weak immune response;
- Cushing’s disease (caused by an excess of cortisol hormone);
- high blood sugar;
- had any prior use of MEDROL.

Before you have any operation, tell your doctor, dentist or anesthetist that you are taking MEDROL.

Pregnancy and breast feeding
You must tell your doctor if you are pregnant, think you might be pregnant or are trying to become pregnant as this medicine could slow the baby’s growth.

You should tell your doctor if you are breast feeding as small amounts of corticosteroid medicines may get into breast milk.

Children:
Corticosteroids can affect growth in children.

INTERACTIONS WITH THIS MEDICATION

Before taking MEDROL talk to your doctor about all your other medications, including those you bought without prescription, herbal or natural products. Especially if you are taking the following:
- drugs to treat glaucoma and epilepsy such as acetazolamide
- drugs to prevent or alleviate nausea and vomiting such as aprepitant or fosaprepitant
- drugs to treat cancer such as aminogluthethimide or cyclophosphamide
- drugs to “thin” the blood: Anticoagulants such as acenomoumarol, phenindione and warfarin
- drugs to treat myasthenia gravis (a muscle condition) such as distigmine and neostigmine
- antibiotics and antifungals (such as ketoconazole, itraconazole, amphotericin B, erythromycin, clarithromycin, troleandomycin, rifampicin and rifabutin)
- aspirin and non-steroidal anti-inflammatory medicines (also called NSAIDs) such as ibuprofen
• drugs to treat epilepsy such as barbiturates, carbamezipine, phenytoin and primidone
• drugs for heartburn and acid indigestion such as cimetidine
• Cyclosporine
• drugs for heart problems or high blood pressure as digoxin and diltiazem
• water pills (Diuretics)
• hormone replacement therapy or hormonal oral contraceptive
• drugs to treat HIV infections such as indinavir or ritonavir
• pancuronium or vecuronium – or other medicines called neuromuscular blocking agents which are used in some surgical procedures
• tacrolimus – used following an organ transplant to prevent rejection of the organ
• vaccines – tell your doctor or nurse if you have recently had, or are about to have any vaccination
• drugs to treat diabetes
• drugs to treat tuberculosis
• drugs to treat high cholesterol (cholestryramine)

Driving and Using Machines
MEDROL may cause dizziness, vertigo, vision problems and fatigue. If you experience these side effects you should not drive or operate machinery.

PROPER USE OF THIS MEDICATION

Usual dose: Between 4 mg to 48 mg daily, depending on your condition and how severe it is.

Your doctor may tell you to take your daily dose as a single dose or in divided doses.

Swallow the tablets with a drink of water. Do not eat grapefruit or drink grapefruit juice while taking MEDROL.

When your condition has improved, your dose will be reduced gradually.

MEDROL should not be stopped abruptly. Do not stop taking MEDROL without talking to your doctor.

Overdose:
In case of drug overdose, contact a health care practitioner, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

Missed Dose:
Take the missed dose as soon as you remember it. However, if it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Like all medicines, MEDROL can have side effects although not everybody gets them

MEDROL may hide symptoms of infections, may cause latent infections to become active, and may induce infections by normally inoffensive organisms due to lowered body resistance.

Potential side effects of MEDROL include:

Allergic Reactions:
• anaphylaxis (a severe, life-threatening allergic reaction)
• cardiac arrest
• bronchospasm (narrowing of the airway)

Cardiovascular:
• heart failure
• heart attack
• arrhythmia (irregular heartbeat)
• high and low blood pressure
• blood clots
• thrombophlebitis (vein inflammation)
• thrombosis (blood clot within a blood vessel)

Dermatologic:
• thin fragile skin
• impaired wound healing
• swelling
• ecchymosis (spots caused by ruptured blood vessels)
• petechiae (reddish spot containing blood that appears in skin)
• stretch marks
• dry, scaly skin
• rash
• redness
• itching
• acne
• increased sweating
• lightening or darkening of an area of skin
• abscess
• suppressed reactions to skin tests
• thinning hair

Endocrine and Metabolism:
• development of Cushingoid state (abnormal bodily condition caused by excess corticosteroids)
• moon face (enlargement of chin and forehead)
• weight gain
• abnormal fat deposits
• suppression of pituitary-adrenal axis (a condition that could lead to disabling the body’s responses to physiological stress such as severe infections or trauma)
• suppression of growth in children
• abnormal hair growth
• new symptoms of diabetes

Gastrointestinal:
• stomach ulcer
• stomach bleeding
• inflammation of the pancreas and esophagus
• perforation of the bowel
• nausea
• vomiting or altered sense of taste (with rapid administration of large doses)
• abdominal pain
• bloating
• diarrhea
• indigestion
• bowel/bladder dysfunction
• increased appetite
• peritonitis

Hepatic:
• enlarged liver

Musculoskeletal:
• loss of muscle mass
• muscle weakness
• muscle pain
• malaise (feeling of general discomfort or uneasiness)
• osteoporosis
• pathological fractures
• vertebral compression fractures
• tendon rupture, (particularly of the Achilles tendon)
• Charcot joint disease (neuropathic arthropathy)
• joint pain

Neurologic:
• seizures
• headache
• dizziness
• amnesia
• vertigo
• pain and tenderness
• impaired sensation, strength, and reflexes
• sensation of tingling, tickling, prickling, or burning of a person's skin

Ophthalmologic:
• cataracts
• increased intraocular pressure
• glaucoma

Psychiatric:
• anxiety
• confusion
• depression
• hallucination
• emotional instability
• euphoria (intense feelings of well-being, elation, happiness, excitement and joy)
• insomnia
• mood swings
• personality changes
• suicidal ideation

Sexual Function/Reproduction:
• menstrual irregularities
• increased or decreased motility and number of sperm

Hemotology:
• Above normal white blood cell count
• Above normal cholesterol or triglycerides
• Abnormal blood tests (ex. liver enzymes and urea)

Other:
• fatigue, hiccups, swelling

### SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

<table>
<thead>
<tr>
<th>Symptom / effect</th>
<th>Talk with your doctor or pharmacist</th>
<th>Seek IMMEDIATE medical attention</th>
</tr>
</thead>
<tbody>
<tr>
<td>Burst or bleeding ulcers: symptoms of which are stomach pain, bleeding from the back passage, black or bloodstained stools and/or vomiting blood</td>
<td>Only if severe</td>
<td>√</td>
</tr>
<tr>
<td>Flare up of a previous TB: symptoms of which could be coughing blood or pain in the chest</td>
<td></td>
<td>√</td>
</tr>
<tr>
<td>Infection: symptoms might include a raised temperature and feeling unwell.</td>
<td>In all cases</td>
<td>√</td>
</tr>
<tr>
<td>High blood pressure (symptoms of which are headaches or generally feeling unwell)</td>
<td>In all cases</td>
<td>√</td>
</tr>
<tr>
<td>Swelling</td>
<td>In all cases</td>
<td>√</td>
</tr>
<tr>
<td>Cramps and spasms</td>
<td>In all cases</td>
<td>√</td>
</tr>
<tr>
<td>Vision changes</td>
<td>In all cases</td>
<td>√</td>
</tr>
<tr>
<td>Feeling depressed, including thinking about suicide</td>
<td>In all cases</td>
<td>√</td>
</tr>
<tr>
<td>Feeling high (mania) or moods that go up and down</td>
<td>In all cases</td>
<td>√</td>
</tr>
<tr>
<td>Feeling anxious, having problems sleeping, difficulty in thinking or being confused and losing your memory</td>
<td>In all cases</td>
<td>√</td>
</tr>
<tr>
<td>Mental/mood changes (such as mood swings, depression, suicidal thinking, agitation, anxiety)</td>
<td>In all cases</td>
<td>√</td>
</tr>
<tr>
<td>Feeling, seeing or hearing things which do not exist.</td>
<td>In all cases</td>
<td>√</td>
</tr>
<tr>
<td>Increased thirst/urination</td>
<td>In all cases</td>
<td>√</td>
</tr>
</tbody>
</table>
### SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

<table>
<thead>
<tr>
<th>Symptom / effect</th>
<th>Talk with your doctor or pharmacist</th>
<th>Seek IMMEDIATE medical attention</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fast/pounding/ irregular heartbeat</td>
<td>Only if severe</td>
<td>√</td>
</tr>
<tr>
<td>Acne</td>
<td>In all cases</td>
<td>√</td>
</tr>
<tr>
<td>Poor wound healing</td>
<td></td>
<td>√</td>
</tr>
<tr>
<td>Thinning of skin</td>
<td></td>
<td>√</td>
</tr>
<tr>
<td>Increased hair growth</td>
<td></td>
<td>√</td>
</tr>
<tr>
<td>Dizziness, fatigue, weakness, shortness of breath (congestive heart failure)</td>
<td>Only if severe</td>
<td>√</td>
</tr>
<tr>
<td>Muscle weakness</td>
<td>In all cases</td>
<td>√</td>
</tr>
<tr>
<td>Bone/joint pain</td>
<td></td>
<td>√</td>
</tr>
<tr>
<td>Prone to bone fracture or breaking</td>
<td></td>
<td>√</td>
</tr>
</tbody>
</table>

This is not a complete list of side effects. For any unexpected effects while taking MEDROL, contact your doctor or pharmacist.

### REPORTING SUSPECTED SIDE EFFECTS

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

- Report online at [www.healthcanada.gc.ca/medeffect](http://www.healthcanada.gc.ca/medeffect)
- Call toll-free at 1-866-234-2345
- Complete a Canada Vigilance Reporting Form and:
  - Fax toll-free to 1-866-678-6789, or
  - Mail to: Canada Vigilance Program
    Health Canada
    Postal Locator 0701E
    Ottawa, Ontario
    K1A 0K9

Postage paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect™ Canada Web site at [www.healthcanada.gc.ca/medeffect](http://www.healthcanada.gc.ca/medeffect).

**NOTE:** Should you require information related to the management of side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice.

### HOW TO STORE IT

Store between 15°C and 30°C in the original package. Do not take MEDROL after the expiry date shown on the package. Keep out of reach and sight of children.

### MORE INFORMATION

This document plus the full Product Monograph, prepared for health professionals can be found at:
http://www.pfizer.ca
or by contacting thesponsor, Pfizer Canada Inc., at: 1-800-463-6001.

This leaflet was prepared by Pfizer Canada Inc.

Last revised: 20 March 2017